University of Hertfordshire

  • Dalia M Dawoud
  • Omneya Mohamed
  • Nancy Awad
View graph of relations
Original languageEnglish
Publication statusAccepted/In press - 14 Aug 2018
EventISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems - Centre de Convencions Internacional de Barcelona, Barcelona, Spain
Duration: 10 Nov 201814 Nov 2018


ConferenceISPOR Europe 2018
Internet address


To estimate the direct medical and non-medical costs of managing severe rheumatoid arthritis (RA) in the Kingdom of Saudi Arabia
(KSA) and to assess the budget impact of introducing the new oral advanced treatments (OATs) in KSA from a payer's perspective.
A budget impact model was developed to assess the costs of current practice in the KSA Ministry of Health hospitals for treating
severe RA patients, compared with three alternative scenarios. Scenario 1 (S1) assumed switching 100% of current severe RA
patients to OATs over 1 year. Scenario 2 (S2) assumed switching 30% of current severe RA patients and 50% of those newlydiagnosed
to OATs, while scenario 3 (S3) assumed switching 30% and 100%, respectively to OATs, both over three years. All
scenarios assumed that OATs had equivalent safety and efficacy to biologics. The cost categories considered included drug
acquisition, preparation and administration, medication transportation and cold chain storage among others. All assumptions made
were based on literature review and key opinion leaders’ interviews.
The current practice total cost was estimated to be over SAR 361 million /year ($1=3.75 SAR). Drug acquisition, monitoring, travel
and accommodation costs for the parenterally-administered biologics were the main drivers of cost. S1, S2 and S3 showed cost
savings of 35%, 10.6% and 10.8%, respectively. The average cost /patient/year decreased from SAR 64,000 in the base case to SAR
45,000 in S1 and to SAR 55,000 in S2 and S3.
Switching severe RA patients to OAT would significantly reduce the cost of severe RA management in KSA. The use of OAT will
significantly reduce the costs associated with parenteral and subcutaneous RA drug administration (travel, accommodation, hospital
visits for drug infusion and outpatient visits) for both the patients and the health systems, freeing-up healthcare resources for other
medical needs

ID: 15531502